अन्य औषधि, खाना र जडीबुटी उत्पादनले Tacrolimus को काम बदल्न सक्छन्। यस पृष्ठका सबै कुरा Tacrolimus कै FDA-स्वीकृत लेबलबाट आएका हुन् — मुख्य गाइडकै स्रोतबाट।
लेबलले जसरी समूह बनाएको छ, त्यसरी नै राखिएको छ। प्रत्येक नाम त्यस औषधिको NepalDoc गाइडसँग जोडिन्छ; लेबलले औषधिको नाम नभई वर्ग मात्र भनेको ठाउँमा लेबलकै शब्द उद्धृत गरिएको छ।
Tacrolimus is prescribed with a given dose of a mycophenolic acid (MPA) product, exposure to MPA is higher with tacrolimus co-administration than with cyclosporine co-administration with MPA, because cyclosporine interrupts the enterohepatic recirculation of MPA while tacrolimus does not.Drugs on Tacrolimus Table 15 displays the effects of other drugs on tacrolimus. Table 15. Effects of Other Drugs/Substances on Tacrolimus Tacrolimus dosage adjustment recommendation based on observed effect of co-administered drug on tacrolimus exposures , literature reports of altered tacrolimus exposures, or the other drug’s known CYP3A inhibitor/inducer status.Tacrolimus को लेबलले २६ औषधिको नाम लिएको छ, जुन NepalDoc मा पनि छन्।
यहाँ नाम भएका यी औषधिका आफ्नै अन्तरक्रिया पृष्ठ पनि छन्:
• Nelfinavir and Grapefruit Juice: Increased tacrolimus concentrations via CYP3A inhibition; avoid concomitant use. Drug/Substance Class or Name Drug Interaction Effect Recommendations Grapefruit or grapefruit juice High dose or double strength grapefruit juice is a strong CYP3A inhibitor; low dose or single strength grapefruit juice is a moderate CYP3A inhibitor.
Strong CYP3A Inducers:Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection .
• Mycophenolic Acid Products: Can increase MPA exposure after crossover from cyclosporine to tacrolimus; monitor for MPA-related adverse reactions and adjust MMF or MPA dose as needed. • Nelfinavir and Grapefruit Juice: Increased tacrolimus concentrations via CYP3A inhibition; avoid concomitant use. • CYP3A Inhibitors: Increased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed. • CYP3A4 Inducers: Decreased tacrolimus concentrations; monitor concentrations and adjust tacrolimus dose as needed.
7.1 Mycophenolic Acid When tacrolimus is prescribed with a given dose of a mycophenolic acid (MPA) product, exposure to MPA is higher with tacrolimus co-administration than with cyclosporine co-administration with MPA, because cyclosporine interrupts the enterohepatic recirculation of MPA while tacrolimus does not. Monitor for MPA-associated adverse reactions and reduce the dose of concomitantly administered mycophenolic acid products as needed.
7.2 Effects of Other Drugs on Tacrolimus Table 15 displays the effects of other drugs on tacrolimus. Table 15. Effects of Other Drugs/Substances on Tacrolimus Tacrolimus dosage adjustment recommendation based on observed effect of co-administered drug on tacrolimus exposures , literature reports of altered tacrolimus exposures, or the other drug’s known CYP3A inhibitor/inducer status. Drug/Substance Class or Name Drug Interaction Effect Recommendations Grapefruit or grapefruit juice High dose or double strength grapefruit juice is a strong CYP3A inhibitor; low dose or single strength grapefruit juice is a moderate CYP3A inhibitor. May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) . Avoid grapefruit or grapefruit juice. Strong CYP3A Inducers:Antimycobacterials (e.g., rifampin, rifabutin), anticonvulsants (e.g., phenytoin, carbamazepine and phenobarbital), St John’s wort May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection . Increase tacrolimus dose and monitor tacrolimus whole blood trough concentrations . Strong CYP3A Inhibitor: Protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir, ritonavir), azole antifungals (e.g., voriconazole, posaconazole, itraconazole, ketoconazole), antibiotics (e.g., clarithromycin, troleandomycin, chloramphenicol), nefazodone, letermovir, Schisandra sphenanthera extracts May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). A rapid, sharp rise in tacrolimus levels may occur early, despite an immediate reduction of tacrolimus dose . Reduce tacrolimus dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations . Early and frequent monitoring of tacrolimus whole blood trough levels should start within 1-3 days and continue monitoring as necessary . Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., erythromycin, fluconazole), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) . Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed . Other drugs, such as: Magnesium and aluminum hydroxide antacids Metoclopramide May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) . Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed . Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed . Caspofungin May decrease tacrolimus whole blood trough concentrations. Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed . Direct Acting Antiviral (DAA) Therapy The pharmacokinetics of tacrolimus may be impacted by changes in liver function during DAA therapy, related to clearance of HCV virus. Close monitoring and potential dose adjustment of tacrolimus is warranted to ensure continued efficacy and safety .
Tacrolimus गाइड · सबै अन्तरक्रिया पृष्ठहरू · औषधि A–Z
यो पृष्ठले Tacrolimus को FDA-स्वीकृत लेबलको सारांश जानकारीका लागि दिन्छ — यो चिकित्सकीय सल्लाह होइन। तपाईंले लिने हरेक औषधि, सप्लिमेन्ट र जडीबुटी उत्पादनबारे आफ्नो डाक्टर वा फार्मासिस्टलाई सधैं भन्नुहोस्।
यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।
नेपालडकका सबै खण्ड, एकै ठाउँमा।
विशेषज्ञताअनुसार नेपालभरका डाक्टर खोज्नुहोस्।